Status:
COMPLETED
The Effect of Semaglutide on Pituitary Function
Lead Sponsor:
University of Tartu
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.
Detailed Description
The randomized blinded placebo-controlled clinical trial is conducted on 10 healthy volunteers. 5 study subjects receive once 7 mg of oral semaglutide and once placebo. 5 study subjects receive once ...
Eligibility Criteria
Inclusion
- Age 18-50 years
- The body weight \>65 kg
Exclusion
- presence of chronic illness
- the daily use of medications
- pregnancy
- lactation.
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04865744
Start Date
May 19 2021
End Date
September 30 2021
Last Update
February 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tartu University Hospital
Tartu, Estonia, 51004